# EXPEDITION 3

Source: https://onco.cc/trials/da-trial-expedition3/  
OnCo record `da-trial-expedition3` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EXPEDITION 3 tested solanezumab in mild Alzheimer’s disease and did not meet its primary endpoint. It is included as a negative amyloid-antibody result.

## Summary

A large phase 3 trial of an amyloid antibody that did not slow clinical decline as designed. Listed so the pipeline layer includes failures, not only approvals.

## Fields

- Kind: Trial
- Status: negative
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Registry id: NCT01900665
- Phase: 3
- Setting: Mild Alzheimer’s disease
- Sponsor: Eli Lilly
- Enrolled: 2129
- Result: Primary endpoint not met.
- Outcomes: Primary clinical endpoint: Solanezumab vs Placebo

## Sources

- ClinicalTrials.gov NCT01900665: https://clinicaltrials.gov/study/NCT01900665

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/)
- companies: [Eli Lilly](https://onco.cc/companies/da-lilly/)
- roadmaps: [Anti-amyloid medicines](https://onco.cc/roadmaps/da-roadmap-anti-amyloid/)

---
JSON: https://onco.cc/api/v1/entities/da-trial-expedition3.json